From Financial Modeling Prep: 2025-03-13 07:00:02

Insmed Incorporated (NASDAQ:INSM) has a ROIC of -46.16%, lower than its WACC of 10.76%, indicating inefficient capital utilization. Amicus Therapeutics (NASDAQ:FOLD) has a ROIC of 7.53% and a WACC of 7.87%, nearly covering its cost of capital. Halozyme Therapeutics (NASDAQ:HALO) shines with a ROIC of 22.84% and a WACC of 9.26%, showing efficient capital use.



Read more at Financial Modeling Prep:: Insmed Incorporated’s Capital Efficiency Compared …